PBMC mediated ADCC Assay Service
Background Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
In the field of immuno-oncology and therapeutic antibody development, comprehending the mechanism of action of antibody-dependent cellular cytotoxicity (ADCC) is crucial. At Creative Biolabs, we offer specialized PBMC-mediated ADCC assay services designed to accurately measure the cytotoxic potency of therapeutic antibodies through immune-mediated processes. Leveraging cutting-edge technologies and a team of highly experienced professionals, we provide reliable, reproducible, and detailed results for your research and development needs.
Why Choose PBMC-Mediated ADCC Assays?
ADCC is a critical immune response where Fc receptor-bearing effector cells like PBMCs recognize and kill antibody-coated tumors or infected cells. The ADCC mechanism is vital for the effectiveness of many therapeutic antibodies, making this assay an essential tool in drug development and immunotherapy research. By assessing ADCC activity, researchers can predict the therapeutic potential and optimize the efficacy of antibody-based treatments.
PBMC-Mediated ADCC Assay Service
Our PBMC-mediated ADCC assay service provides a comprehensive and reliable platform for evaluating the cytotoxic capabilities of therapeutic antibodies. PBMCs are isolated from human blood and used as effector cells in this assay, which measures the ability of antibodies to induce cell-mediated lysis of target cells. Our service employs advanced techniques to ensure high sensitivity and specificity, allowing for accurate characterization of an antibody's potency. With our robust PBMC-Mediated ADCC Assay, researchers and pharmaceutical companies can gain critical insights into the efficacy and safety profile of their antibody candidates, facilitating the development of more effective treatments.
Short Protocol
|
Target Cells:
|
BT-474 cells
|
|
Effector Cells:
|
PBMC
|
|
Numbers of Donors
|
3
|
|
E:T ratio:
|
20:1
|
|
Incubation:
|
20 hours at 37°C
|
|
Number of Test Concentration:
|
8 concentrations
|
|
Dye:
|
Calcein AM
|
|
Detection Method:
|
High-content imaging
|
|
Control:
|
hIgG1 isotype control
|
Workflow
Publication
This study introduces a novel flow cytometry-based ADCC assay that overcomes limitations of traditional methods like the radioactive 51Cr release assay. Using CFSE to label target cells, it enables precise quantification of cell death while distinguishing between live/dead cells and target/effector populations. Compared to calcein-AM assays, it shows superior sensitivity, specificity, and reproducibility. The method works with both fresh and frozen PBMCs, making it ideal for clinical trials requiring sample transport. Validated as a robust tool, this standardized approach could accelerate development of ADCC-dependent antibody therapies, offering a safer and more reliable alternative for research and clinical applications.
Fig.1 ADCC bioassay assessment using frozen NK cell lines and PBMCs.1
Advantages of Our PBMC-Mediated ADCC Assay Services
-
Precision and Sensitivity
The use of Calcein AM staining and high content imaging system enhances assay sensitivity and allows for precise measurement of cytotoxicity at a single-cell level.
By employing PBMCs as effector cells, our assay closely mimics the physiological environment, providing more relevant and translatable data for therapeutic antibody efficacy.
Our team of scientists possesses extensive experience in immunoassays and drug development, ensuring you receive comprehensive support and high-quality results.
FAQs
Q1: Why should I choose PBMCs over immortalized cell lines for my ADCC assay?
A1: Using PBMCs as effectors better reflects real immune responses, since they contain diverse immune cells like NK cells. This gives more clinically relevant ADCC data that captures your antibody's true therapeutic potential.
Q2: How does your assay overcome the issue of donor-to-donor variability in ADCC activity?
A2: Our standardized protocol uses multiple healthy donors and introduces CX1:1 - target cell killing at a 1:1 NK-to-target ratio. This normalized metric enables reliable, donor-independent comparison of your ADCC results.
Q3: Can your service work with a limited supply of patient-derived cells?
A3: Our optimized approach works efficiently with small samples. Using cryopreserved PBMCs and sensitive flow cytometry, we extract maximum data from limited cell numbers, perfect for valuable clinical specimens.
Customer Review
-
Enhanced Reproducibility and Consistency
Creative Biolabs' PBMC-mediated ADCC assay service has greatly enhanced our data reproducibility. Their optimized protocol for cryopreserved PBMCs eliminates variability seen with fresh cells, delivering consistent, reliable results across all our experiments. - J.D.*
-
Superior Sensitivity for Low-Dose Antibodies
Creative Biolabs' flow cytometry-based ADCC assay proved far more sensitive than our calcein-AM tests, reliably detecting activity at lower antibody concentrations - crucial for characterizing our low-dose therapeutic's potency. - S.A.*
Discover How We Can Help - Request a Consultation.
Related Services
Analytical and Bioassay Quality Control
Creative Biolabs excels in immunotherapy, offering expertise in mammalian and microbial cell line development. Their advanced analytics identify optimal clones, which they optimize for high productivity and scalable manufacturing through tailored cell culture conditions.
Learn More →
Cell Culture Process Development Services
Creative Biolabs specializes in immunotherapy, developing high-yield mammalian and microbial cell lines. Using advanced analytics, they select optimal clones and optimize culture conditions to ensure scalable, high-productivity manufacturing tailored to your needs.
Learn More →
Partner with Creative Biolabs
At Creative Biolabs, we are committed to accelerating your drug discovery and development process. Our PBMC-mediated ADCC assay services provide a reliable and efficient route to evaluate the cytotoxic potential of therapeutic antibodies, fostering the development of promising immunotherapies. For more information or to discuss your specific requirements, please contact us today.
Reference
-
Yamashita, M., et al. "A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells." Scientific Reports 6 (2016): 19772. Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.1038/srep19772
